Cargando…

Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study

OBJECTIVE: Since 2016, the Chinese government has been regularly implementing the National Reimbursement Drug List Negotiation (NRDLN) to improve the accessibility of drugs. In the second round of NRDLN in July 2017, 18 anticancer drugs were included. This study analyzed the impact of the NRDLN on t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Hong, Zhu, Jingmin, Zhou, Yingyu, Shan, Linghan, Li, Cui, Cui, Yu, Kang, Zheng, Jiao, Mingli, Liu, Huan, Gao, Lijun, Wu, Qunhong, Hao, Yanhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Public Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283976/ https://www.ncbi.nlm.nih.gov/pubmed/35844892 http://dx.doi.org/10.3389/fpubh.2022.921093

Ejemplares similares

Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China
por: Mingge, Xia, et al.
Publicado: (2023)

Impacts of adjustment of National Reimbursement Drug List on orphan drugs volume and spending in China: an interrupted time series analysis
por: Yi, Hongbin, et al.
Publicado: (2023)

Reporting quality of economic evaluations of the negotiated Traditional Chinese Medicines in national reimbursement drug list of China: A systematic review
por: Yan, Juntao, et al.
Publicado: (2023)

Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study
por: Cai, Lele, et al.
Publicado: (2022)

Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement
por: Macabeo, Bérengère, et al.
Publicado: (2023)

Differences in reimbursement listing of anticancer therapies in China: an observational study
por: Guan, Xiaodong, et al.
Publicado: (2020)

The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China
por: Zhang, Yichen, et al.
Publicado: (2021)

Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review
por: He, Zixuan, et al.
Publicado: (2023)

Were economic evaluations well reported for the newly listed oncology drugs in China’s national reimbursement drug list
por: Liu, Liu, et al.
Publicado: (2022)

Emergency Physician Reimbursement: Getting Shortchanged or Shrewdly Negotiating?
por: Venkatesh, Arjun K., et al.
Publicado: (2020)

Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis
por: Huang, Cong, et al.
Publicado: (2021)

Effect of reimbursement restriction policy on the use of benzodiazepines in the Netherlands: an interrupted time series analysis
por: Stoker, Lennart Jan, et al.
Publicado: (2019)

Impacts of National Drug Price Negotiation on Expenditure, Volume, and Availability of Targeted Anti-Cancer Drugs in China: An Interrupted Time Series Analysis
por: Sun, Yan, et al.
Publicado: (2022)

Evidence for the effectiveness of anti-hypertensive medicines included on the Chinese National Reimbursement Drug List
por: Liu, Wenbin, et al.
Publicado: (2019)

Epidemiological trend in scarlet fever incidence in China during the COVID-19 pandemic: A time series analysis
por: Ma, Yunxia, et al.
Publicado: (2022)

Adapting pharmaceutical reimbursement policies to manage spending on high-priced drugs
por: Docteur, Elizabeth, et al.
Publicado: (2015)

Interrupts-List
por: Cherix, E
Publicado: (1990)

How health technology reassessment can support disinvestment in China’s national drug reimbursement list
por: Shi, Lizheng, et al.
Publicado: (2023)

Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis
por: Wang, Ni, et al.
Publicado: (2021)

What fragile factors hinder the pace of China’s alleviation efforts of the poverty-stricken population? A study from the perspective of impoverishment caused by medical expenses
por: Wang, Jiahui, et al.
Publicado: (2022)

Chinese Herbal Therapy and Western Drug Use, Belief and Adherence for Hypertension Management in the Rural Areas of Heilongjiang Province, China
por: Li, Xia, et al.
Publicado: (2015)

Critical Appraisal of Reimbursement List in Bosnia and Herzegovina
por: Mujkic, Sabina, et al.
Publicado: (2017)

Budget Impact of Introducing Linagliptin into Bosnia and Herzegovina Health Insurance Drug Reimbursement List in 2016-2018
por: Catic, Tarik, et al.
Publicado: (2017)

Can integration reduce inequity in healthcare utilization? Evidence and hurdles in China
por: Zhao, Miaomiao, et al.
Publicado: (2019)

Time to reimbursement of novel anticancer drugs in Europe: a case study of seven European countries
por: Post, H.C., et al.
Publicado: (2023)

Consumption and cost trends of EGFR TKIs: influences of reimbursement and national price negotiation
por: Wu, Di, et al.
Publicado: (2022)

The Impact of Drug Reimbursement Policy on Rates of Testosterone Replacement Therapy among Older Men
por: Piszczek, Jolanta, et al.
Publicado: (2014)

“Budget Impact Analyses”: A Practical Policy Making Tool for Drug Reimbursement Decisions
por: Jamshidi, Hamid Reza, et al.
Publicado: (2014)

Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2020)

The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data
por: Yang, Yu, et al.
Publicado: (2023)

Impact of delisting OTC medicines from reimbursement list
por: Chytilová, Petra, et al.
Publicado: (2015)

Economic burden and health related quality of life of ultra-rare Gaucher disease in China
por: Qi, Xinye, et al.
Publicado: (2021)

The impact of reimbursement negotiations on cost and availability of new pharmaceuticals: evidence from an online experiment
por: Wettstein, Dominik J., et al.
Publicado: (2020)

Inequity in Health Services Utilization in Economically Underdeveloped Regions of Northeast China
por: Zhang, Xin, et al.
Publicado: (2022)

Price-Cutting Trends in New Drugs after Listing in South Korea: The Effect of the Reimbursement Review Pathway on Price Reduction
por: Kim, Sungju, et al.
Publicado: (2020)

Patient Satisfaction with Hospital Inpatient Care: Effects of Trust, Medical Insurance and Perceived Quality of Care
por: Shan, Linghan, et al.
Publicado: (2016)

Targeting vulnerable groups of health poverty alleviation in rural China— what is the role of the New Rural Cooperative Medical Scheme for the middle age and elderly population?
por: Wang, Nianshi, et al.
Publicado: (2020)

A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries
por: Czech, Marcin, et al.
Publicado: (2020)

Catastrophic health expenditure incidence and its equity in China: a study on the initial implementation of the medical insurance integration system
por: Liu, Huan, et al.
Publicado: (2019)

Workplace violence against nurses in Chinese hospitals: a cross-sectional survey
por: Jiao, Mingli, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qvbh50htptkrbubjd9faomfulf